Introduction

24
Glucagon is a 29 amino acid peptide which is one of multiple hormones that modulates 25 glucose production or utilisation to regulate blood glucose levels. It is also a biomarker for 26 pathologies such as diabetes, pancreatic cancer or certain neuroendocrine tumours [1] . It is 27 known to be degraded by peptidases such as dipeptidyl peptidase IV [2] [3] and 28 consequently blood samples are typically collected in tubes containing protease inhibitors. 29
Endogenous glucagon levels in healthy patients are reported between 25-80 pg/mL, which 30 may be raised by about 10 pg/mL in pancreatic cancer patients, and can reach up to 160 31 Furthermore, as glucagon is produced endogenously, this presents additional experimental 48 challenges as an authentic analyte free matrix cannot be obtained to construct calibration 49 standards. Either a standard addition, surrogate analyte, or a surrogate matrix approach 50 must therefore be used [15] [16] . 51
In the standard addition based approach, analyte is spiked on top of the authentic matrix to 52 create a calibration line, which is extrapolated to measure concentrations below the matrix's 53 endogenous value. However the USA FDA Guidance for Bioanalytical Method Validation 54
[17] actively discourages the extrapolation of calibration curves beyond their range. The 55 surrogate analyte based approach uses an analogue to the analyte in place of the analyte 56 itself in calibration samples. As this will have a Selected Reaction Monitoring (SRM) 57 transition unique from the authentic analyte these can be prepared in authentic biological 58 matrix [15] . However, this approach requires the relationship between the authentic and 59 surrogate analyte to be thoroughly investigated, the approach is not commonly used, and is 60 not considered in the FDA [17] or EMA guidelines [18] . Alternatively, in the surrogate matrix 61 approach, calibration lines are constructed by spiking analyte into a surrogate matrix. QCs 62 can be prepared in actual sample matrix, and the accuracy calculated to demonstrate the 63 absence of a matrix effect. Surrogate matrices may be the authentic matrix stripped of 64 analyte (e.g. by charcoal [16] or immuno-afffinity methods [19] ) or an alternative matrix (e.g. 65 protein buffers, dialysed serum [20] ). Although not ideal, the EMA Guideline on bioanalytical
Extraction method for validation 161
Plasma sample (aprotinin stabilised, K3 EDTA) (400 µL) was placed into a 5 mL 162 polypropylene tube and 20 µL of ISWS was added to all non-blank samples. The samples 163
were briefly vortex mixed, precipitated using 3.2 mL of MeCN:H 2 O:NH 3 (72:25:0.1,v/v/v), 164 vortex mixed again, and then centrifuged for 10 minutes at 2300 x g. The supernatant was 165 transferred to a new tube and evaporated to dryness overnight under vacuum. Samples 166 were reconstituted in 800 µL 2% NH 3 (aq) and then vortex mixed. A Bond Elut Plexa 96 167 round-well solid phase extraction (SPE) plate (30 mg) was conditioned using 1 mL MeOH, 168 then equilibrated with 1 mL H 2 0. The samples were loaded, washed with 1 mL 5% MeOH 169 final calibration levels of 25, 45, 75, 100, 200, 400, 600, 900, and 1000 pg/mL, and final QC 176 levels of 25 and 50 pg/mL. The plate was centrifuged for 10 minutes at 2300 x g, and 50 µL 177 of sample injected on to the LC-MS/MS system for analysis. 178
Validation Experiments 179
The validation experiments chosen were based on those described in the latest EMA 180 guidance [18] . Calibration standards were analysed in duplicate with each batch. Data was 181 imported into Watson LIMS 7.2 (Thermo Fisher Scientific Inc, Massachusetts, USA) and 182 linear regression with 1/x 2 weighting was applied to the peak area ratios-concentration plot 183 for the construction of calibration lines. The precision and accuracy of the method was 184 determined by analysis of replicate (n=6) QC samples at four different concentrations (25, 185 50, 100, and 750 pg/mL), and was assessed within a batch (intra-batch, n = 6 replicates) 186 and between batches (inter-batch, 3 batches). The ability to dilute was assessed by diluting 187 an over range dilution sample (7500 pg/mL) 10-fold with blank plasma. Carryover effects 188
were evaluated by injection of blank samples immediately after injection of the highest point 189 in the calibration range. The stability of the glucagon in aprotinin stabilised human plasma was evaluated at the 204 medium and high concentrations in replicate (n=6). Stability was assessed after 205 6 hr 20 min on ice (4 C), after storage for 11 and 75 days at -20°C, and for 7, 11, 51, and 64 206 days at -80°C. Similarly stability was assessed after 4 freeze-thaw cycles from -20 C to 4 C 207 and also 4 freeze cycles from -80 C to 4 C. Stability was similarly assessed in whole 208 blood following storage on ice for 1 hour. The ability to re-inject sample extracts at medium 209 and high concentrations was assessed after storage at +4°C for 6 days. The stability of the 210 stock solution was assessed after storage at -20C for 66 days and that of LLOQ and ULOQ 211 working solutions after 163 days at -20C. 212
213
All results are quoted from batches where the standards and QCs passed our prospectively 214 defined acceptance criteria, which were based on the EMA and FDA guidelines. These 215 required that at least 75% of standards in each batch had back calculated accuracy within 216 15% (20% at the LLOQ) of the nominal concentration, with standards outside these criteria 217 excluded from the regression. QCs in precision and accuracy batches needed to have mean 218 intra-batch accuracy within 20% of the nominal concentration, and intra-batch precision that 219 did not exceed 20%. In other batches at least 2/3 of the individual QCs had accuracy within 220 20% of the nominal concentration, with at least one QC passing criteria at each level. 221
Although the guidelines suggest a 15% criteria (20% at the LLOQ) should be applied to QC 222 performance, they state it can be widened prospectively in special cases. We felt it was 223 justified to raise the QC acceptance criteria to 20% (CV and RE) due to the surrogate matrix 224 nature of the assay. The 20% (RE) acceptance criteria was also applied to plasma, blood 225 and extract stability experiments, as well as to the assessment of the matrix effect in 226 different individuals (matrix factor ratio) and of the effect of haemolysed or hyperlipidaemic 227
plasma. 228
Collection of samples from volunteers to assess endogenous glucagon concentrations 230
Plasma was collected from 12 healthy males and 12 healthy females using glass collection 231 tubes containing K3 EDTA and aprotinin, as described above. Glucagon levels were 232 determined using the qualified LC-MS/MS method. Plasma was collected at the start of the 233 working day and volunteers were not asked to change their usual eating regime. 
Analysis of physiological study samples 243
A selection of the physiological study samples (n=100) were analysed by LGC using the LC-244 MS/MS method described above. Additional QCs prepared in aprotinin stabilised plasma 245 with lithium heparin anticoagulant were analysed to ensure assay performance in the sample 246 matrix. 38 of the study samples were analysed over the calibration range 25-1000 pg/mL, 247 whilst the remainder were analysed over the calibration range 10-1000 pg/mL. For these 248 samples additional calibration points and QCs were included at the 10 and 15 pg/mL levels 249 to evaluate assay performance. Samples (n=105) were also analysed by Imperial College 250 using their established radioimmunoassay method over the calibration range 5 -1000 pg/mL, 251 which is directed against the C-terminal region of glucagon [24] [25]. Samples were analysed 252 upon their first freeze-thaw. 253
254
Results and discussion
255
Method development 256
Analysis of endogenous levels of glucagon by LC-MS/MS poses a significant technical 257 challenge. Not only are the low endogenous concentrations difficult to measure, an 258 endogenous analyte quantitation strategy must be used, and stability issues must be 259
addressed. 260
Extensive assay optimisation was therefore performed to obtain the low 25 pg/mL LLOQ. A 261 QTRAP mass spectrometer was used in SRM mode, and parameters were optimised. 262 Although this is not a particularly specific transition, the intensity was significantly greater 273 than other transitions and was therefore chosen; selectivity was fully investigated during the 274 validation. Resolution settings for Q1 and Q3 were optimal at unit-unit, rather than high-high 275 as reported by others [11] . The optimal ion pairs of the transitions were 697.5/693.8, which 276 corresponds to a 18.5 Da loss. The small difference between our optimal pair, and that 277 cases background noise and interferences were relatively high, as was matrix suppression. 297
UHPLC was chosen for chromatographic separation because it results in greater efficiencies
It was therefore decided to investigate solid phase extraction (SPE) based approaches, as 298 these should lead to cleaner samples with reduced background noise and interferences. 299
These studies are described in the supplementary information. 300
Combining protein precipitation with size exclusion hydrophobic (SEH) SPE was found to 301 reduce the on column matrix effects, whilst providing adequate recovery. To our knowledge 302 this is the first time protein precipitation has been combined with SEH SPE for quantitative 303 peptide analysis, although protein precipitation has been combined with other SPE phases 304 for this purpose [32] . Due to the satisfactory performance of this extraction methodology, 305 alternatives such as immunoaffinity enrichment were not investigated [33] . 306
307
Various UHPLC gradients were investigated to further reduce matrix build-up on the column 308 and it was found that a 4 minute flush at the starting conditions gave the best performance. 309
This gradient combined with the 2D extraction methodology significantly increased the 310 robustness of the assay. 311
Glucagon is known to be degraded by the blood enzymes and consequently sample 312 stabilisation is required [2] . The enzyme inhibitor aprotinin was used to reduce degradation 313 and samples were extracted on ice. As there have been reports of enzyme inhibitors 314 interfering with peptide quantitation [34] assay performance was closely monitored during 315 the validation for any such issues. 316
Surrogate matrix quantitation 318
Several mixtures were screened for their suitability as surrogate matrices. A dilute buffer 319 matrix was evaluated, as such matrices have been shown to be suitable for some assays. 320
[35] [19] . A buffer solution containing a relatively high percentage of BSA was also evaluated 321 to minimise any non-specific analyte binding that may occur. In addition a diluted rat plasma 322 matrix was chosen to investigate whether biological matricies improved assay performance. was expected to take into account recovery differences between the surrogate matrix 333 calibrants (which will necessarily have recovery of 100% for the analyte and IS) and the 334 extracted plasma samples. The internal standard was also expected to take in to account the 335 differences in matrix effect between the two matrices, as well as any small losses that 336 occurred due to non-specific binding that occurred in the injection plate. Whilst the buffer 337 solution selected as the surrogate matrix is of quite a different nature to the plasma samples, 338 assays for small [35] and large molecules [19] have been successfully validated using such 339 an approach, and the validation experiments described later in this manuscript fully assess 340 the assay's performance. It was decided to proceed with this approach rather than 341 investigate alternative matrices such as charcoal stripped plasma. It has been suggested 342 that when a surrogate matrix approach is used that aliquots of the authentic matrix 343 containing the endogenous analyte should be used as QC MED samples and QC HIGH 344 samples should be prepared by spiking analyte in addition to this endogenous level [35] .QC 345 LOW samples are then made by diluting authentic matrix with surrogate matrix, and 346 QC LLOQ samples prepared in pure surrogate matrix. Unfortunately this strategy cannot be 347 used for glucagon quantitation due to its relatively low endogenous levels (LLOQ to 3x 348 LLOQ). It was therefore decided to construct QC LOW using surrogate matrix, and QC MED 349 and QC HIGH samples were prepared by spiking analyte on top of the endogenous level in 350 authentic matrix. Due to the low endogenous levels it was decided to limit the LOW level to 2 351
x LLOQ (rather than the 3x LLOQ typically used [18] .
Human plasma (K3 EDTA) from a commercial supplier was analysed using the assay to 353 determine its suitability as an authentic matrix. As shown in Supplemental Figure 4 such 354 plasma has a significantly raised background compared to plasma collected from volunteers 355 in house. This may be a result of the lack of stabiliser upon collection, the age of the plasma 356 and/or storage conditions. The raised background makes it unsuitable for the construction of 357 QC samples, and therefore it was decided to use plasma collected in house as the integrity 358 of these samples could be ensured. Similarly, sample collection and storage regimes for 359 any clinical samples should be carefully controlled to ensure their integrity. 360
Validation 361
The precision and accuracy of the method was determined by analysis of replicate (n=6) QC 362 samples at four different concentrations (25, 50, 100 and 750 pg/mL). Precision and 363 accuracy was assessed within a batch (intra-batch, n = 6 replicates) and between batches 364 (inter-batch, 3 batches). The intra-and inter-assay precision did not exceed 20%, nor did the 365 intra-and inter-assay accuracy demonstrating the method was performing robustly 366 (Supplemental Table 1 ). No carryover after high calibration standards was observed and no 367 potentially interfering peaks were observed during the selectivity assessment. The 10-fold 368 dilution of an over range QC sample (7500 pg/mL) with control plasma was used to 369 demonstrate the absence of dilution effects (Supplemental Table 2 ). 370 The analogue Internal standard (IS) compensated for differences in suppression observed 373 by the analyte in different matrices, with mean matrix factor (MF) ratios being 1.08 and 1.05 374 at the medium and high level; a perfect correction would have a ratio of 1 (Supplemental 375 Table 3) . 376
Recovery was assessed across three different batches with a minimum of 3 replicates at 377 each level. In order to investigate whether the nature of the matrix affected recovery it was 378 assessed from; samples where the analyte was spiked into control matrix then immediately 379 extracted, samples where the analyte was spiked into 3 freshly acquired matrix pools then 380 immediately extracted, and finally from samples where the analyte was spiked into matrix 381 then stored for a week at -80 C before extraction (Supplemental Table 4 ). No significant 382 difference between these experiments was observed, which gave an average analyte 383
recovery of 51.2% 384
Acceptable sensitivity is usually demonstrated by assessing whether the analyte response at 386 the LLOQ level is at least 5 times [18] the average response due to background noise 387 (Figure 2) , which was the case for all accepted batches. It is then assumed that an unknown 388 sample at the LLOQ concentration would also have a similarly acceptable response. 389
However, this will not necessarily be the case for surrogate matrix assays, due to differences 390 in the recovery and matrix factor between the surrogate and authentic matrices. By taking 391 into account the mean analyte recovery (51.2%) and mean matrix factor (0.746) for our 392 assay, it was calculated that signal-to-noise (S/N) at the LLOQ should be at least 13.1 to 393 ensure that S/N for an authentic sample at the LLOQ level 5 (assuming an unchanged 394 background level). This criterion was not formally part of our validation, but it was met by all 395 accepted batches. 
400
Although we used Aprotinin, a degree of glucagon instability within human plasma was 401 apparent and most experiments gave results outside the acceptance criteria of 20% of the 402 nominal concentration (Table 1) . Even if 0 hr concentrations were used, to take into account 403 any assay bias or preparation differences, many results remain outside 20% of this 404 concentration. Glucagon plasma samples were found to be within 23.7% of their nominal 405 concentrations following storage at the extraction temperature (+4C) for 6 hours 20 406 minutes, and within 21.4% of their 0 hr concentration following storage for 75 days at -20C, 407 or within 20.2% following storage for 51 days at -80C. Greater instability was observed 408 following multiple freeze-thaw cycles, and these should therefore be minimised during 409
analysis. The accuracy of the method is therefore limited by the sub-optimal sample 410 stabilisation procedure. The effect of such pre-analytical parameters has been described by 411 others [36] , and future assay development should include an evaluation of these. For 412 example, stability would likely be improved if specific DPP-IV inhibitors were used [37] , 413 rather than the broad serine protease inhibitor Aprotinin. As stability in Human K3 EDTA plasma with Aprotinin stabilisation did not pass our 416 acceptance criteria, the method is described as qualified, rather than validated. However, the 417 instability was moderate, and the data generated is likely to "fit for purpose" for many criteria. However the assay may still be considered "fit-for-purpose". 428
Fit-for-purpose assay-An assay where its performance characteristics have been assessed 429
and are reliable for the intended application. For example, a biomarker assay which is used 430 to assess a sole pharmacodynamic end point requires better performance characteristics 431 than an assay used as part of a panel of measurements. 432 
438
Statistics are of n=6 replicates, expect for 64 days (-80C), which have n=4 and n=5 replicates at the MED and HIGH level respectively.
The ability to re-inject extracts was demonstrated after storage at +4°C for 6 days 440 (Supplemental Table 5 ). The stability of stock and working solutions of glucagon, which were 441 stored at -20 C when not in use, was demonstrated for 67 and 163 days respectively 442 (Supplemental Table 6 ). 443
The stability of glucagon in Aprotinin stabilised whole blood following storage on ice for 1 444 hour was found to be within acceptance criteria (Supplemental Table 7) . 445
446
Haemolysed samples (plasma spiked with 3% whole blood) contained a large neighbouring 447 peak, and did not pass acceptance criteria, demonstrating haemolysed samples cannot be 448 accurately quantified using this method (Supplemental Figure 5) . The presence of 449 hyperlipidaemic plasma did not significantly affect the quantitation of glucagon 450 (Supplemental Table 8 ).
452 453
Using the qualified LC-MS/MS method to assess endogenous glucagon concentrations from 454 volunteers 455
Plasma was collected from 12 healthy males and 12 healthy females and glucagon levels 456 determined using the qualified LC-MS/MS method. As shown in Table 2 levels agreed well 457 with the 25-80 pg/mL range determined by RIA [1]. Chromatograms from samples which 458 gave glucagon concentrations above the LLOQ showed good signal to noise ratios (Figure  459 3). Some samples which gave glucagon concentrations below the LLOQ showed 460 integratable peaks (Figure 3 ) and their approximate concentrations were determined by 461 extrapolation (Table 2 ) 462 The majority of samples (58%) gave glucagon concentrations above the 25 pg/mL qualified 471 LLOQ, demonstrating the assay's utility for endogenous level analysis. However as glucagon 472 concentrations in some individual plasmas were very close to, or below, this level, for 473 subsequent analysis we decided to include additional standards and QCs at the 10 and 15 474 pg/mL concentrations. These allowed assessment of whether a lower LLOQ could be 475 achieved on a batch to batch basis. The acceptable LLOQ was experimentally determined 476 by ensuring that its performance was within acceptance criteria (signal to noise >5, and CV 477 and RE (<20%). 478
To assess whether quantitation was reproducible at the endogenous level, samples 479 containing endogenous glucagon were pooled together, and analysed multiple times in 3 480 different batches (n=6 replicates in each batch) using the approach above. An overall mean 481 of 26.5 pg/mL was observed with an overall CV of 19.8%, demonstrating reproducible 482 quantification at the endogenous level (Supplemental Table 9 ). QCs (n=6 replicates) 483 consistently performed within 20% (RE and CV) at the 15 pg/mL level in each of the 3 484 batches, and were within 20% (RE and CV) at the 10 pg/mL level in 2 out of the 3 batches 485 (Supplemental Table 10 ). This allowed the LLOQ to be reduced from the 25 pg/mL level in 486 the qualified assay, to increase the proportional of quantifiable concentrations. 
LC-MS/MS vs. RIA assays for physiological study samples 488
Plasma samples (n= 117) were collected from a physiological study involving the infusion of 489 glucagon. 100 of these samples were analysed using our LC-MS/MS assay and 105 490 samples using the established RIA assay. Both assays contained QC samples, which 491 performed within their established acceptance criteria. 492
Bland-Altman analysis of the 88 common samples shows that the mean bias of the LC/MS-493 MS assay versus the RIA is +45.06 pg/ml with 95% bias confidence intervals of -358.5 to 494 448.6 pg/ml. Inspection of the plot (Figure 4 a) shows that there is a concentration-495 dependent positive bias, particularly at values above 600 pg/ml, which is also evident in the 496 scatter plot (Figure 4 b) This would be expected if the RIA assay was suffering from the 497 hook effect at higher concentrations, which has been reported for other biomarkers such as 498 calcitonin [38] . 
Conclusion
516
The developed procedure is the first peer reviewed LC-MS/MS method capable of 517 quantifying endogenous levels of glucagon in human plasma. Glucagon levels from healthy 518 volunteers agreed well with the range expected from RIA assays. Our method avoids the 519 radioactivity (and precautions this requires) associated with RIA assays, has a shorter 520 extraction time and good precision and accuracy. 521
The 25 pg/mL LLOQ in our qualified assay is a considerable improvement over the lowest 522 LC-MS/MS LLOQ previously reported (250 pg/mL) in the peer reviewed literature [11] . A 10 523 pg/mL LLOQ has been reported in a conference presentation [14], using a highly sensitive 524 QTRAP mass spectrometer. We were on occasion able to see such levels using our 525 instrument, although we performed the qualification using a 25 pg/mL LLOQ to improve 526 assay robustness. Transferring this assay on to a more modern instrument may enable the 527 LLOQ of 10 pg/mL to be achieved routinely. Our 2D extraction procedure was key to 528 achieving such sensitivity, by reducing matrix suppression, background noise, and 529 interferences. To our knowledge this is the first time protein precipitation and size exclusion 530 SPE have been combined for such a purpose for high throughput peptide analysis. Our 531 Volunteer 4 surrogate matrix approach, using a mixture of non-extracted surrogate matrix STDs and QCs 532 and extracted authentic matrix QCs, is also a novel strategy for endogenous peptide 533
analysis. 534
Bland-Altman analysis shows a mean positive bias of the LC/MS-MS method versus the RIA 535 that appears to be a concentration-dependent, as would be expected if the RIA was suffering 536 from the hook effect at higher concentrations. The PK profiles from both assays were similar 537 shapes, and both profiles fitted with the nature of the physiological study suggesting the 538 methods are complementary. 539
The assay's performance has been qualified using experiments described in the latest EMA 540
[18] and FDA [17] guidance and in accordance to the principles of GCP [23] .  Endogenous compounds, such as glucagon, can be quantified using either a 548 standard addition, surrogate analyte, or a surrogate matrix approach. 549  We favoured the surrogate matrix approach as it avoids extrapolation and is 550 described in the EMA Guideline on bioanalytical method validation. 551
Results and Discussion 552
Method development 553
 Extensive optimisation has generated the most sensitive LC-MS/MS method for  Validation experiments performed were based on those described in the latest EMA 564 and FDA guidelines. 565  Most experiments, including the precision and accuracy of the method, were within 566 the prospectively defined acceptance criteria. 567  However, a degree of plasma sample instability was apparent, and it fell outside of 568 our prospectively defined acceptance criteria. 569  The assay is therefore described as qualified, over the range 25 -1000 pg/mL, 570 rather than validated. The assay will however be fit-for-purpose for many 571 
Future Perspectives
591
We believe that experimentally demanding or troublesome immunoassays, such as the 592 glucagon RIA assay, will increasingly become replaced with LC-MS/MS based 593 methodologies to circumvent issues with cross reactivity, increase sample throughout and 594 avoid the use of radioactivity. To achieve the low LLOQs often required we also believe that 595 approaches such as 2D extraction will become more commonly used. For regulated 596 bioanalytical studies of endogenous compounds, strategies such as surrogate matrix 597 quantitation, which avoids the need to extrapolate the calibration curve, will become the 598 favoured approach. 599
